Related Experiment Video

Updated: Aug 6, 2026

Co-immunoprecipitation Assay Using Endogenous Nuclear Proteins from Cells Cultured Under Hypoxic Conditions
09:17

Co-immunoprecipitation Assay Using Endogenous Nuclear Proteins from Cells Cultured Under Hypoxic Conditions

Published on: August 2, 2018

JNK1 as a molecular target to limit cellular mortality under hypoxia

Seema Betigeri1, Refika I Pakunlu, Yang Wang

  • 1Department of Pharmaceutics, Rutgers, The State University of New Jersey, Piscataway, New Jersey 08854-8020, USA.

Molecular Pharmaceutics
|August 8, 2006
PubMed

Insights

Suppressing Jun N-terminal kinase 1 (JNK1) using antisense oligonucleotides or siRNA reduces cell death from hypoxia. This finding suggests JNK1 is a potential target for antihypoxic therapies to improve treatment efficacy in oxygen-deficit conditions.

Area of Science:

  • Cellular Biology
  • Molecular Medicine
  • Pathophysiology

Background:

  • Hypoxia, a common consequence of pathological conditions, severely impacts cellular homeostasis and treatment efficacy.
  • Jun N-terminal kinase 1 (JNK1) is a key mediator of cellular damage during hypoxia.
  • Understanding JNK1's role is crucial for developing novel antihypoxic strategies.

Purpose of the Study:

  • To investigate the effect of suppressing JNK1 activity on cellular survival under hypoxic conditions.
  • To evaluate JNK1 as a therapeutic target for mitigating hypoxia-induced cell death.

Main Methods:

  • Utilized antisense oligonucleotides (ASO) and small interfering RNA (siRNA) to inhibit JNK1 synthesis.
  • Employed liposomal delivery systems for ASO and siRNA in cell cultures.
  • Exposed cells to normoxic and hypoxic conditions to assess JNK1 suppression efficacy.

Main Results:

  • Suppression of JNK1 activity significantly decreased hypoxia-induced cellular mortality.
  • Inhibition of JNK1 limited the caspase-dependent apoptosis signaling pathway.
  • Liposomal delivery of ASO/siRNA effectively reduced JNK1 levels and protected cells from hypoxic damage.

Conclusions:

  • JNK1 is a critical factor in hypoxia-induced apoptosis and cell death.
  • Targeting JNK1 with ASO or siRNA offers a promising therapeutic approach for antihypoxic therapy.
  • JNK1 inhibition may enhance resistance to pathological conditions characterized by oxygen deficit.

More Related Videos

Antagonistic Effect of Jiawei Shengjiang San on a Rat Model of Diabetic Nephropathy: Related to EGFR/MAPK3/1 Signaling Pathway08:15

Antagonistic Effect of Jiawei Shengjiang San on a Rat Model of Diabetic Nephropathy: Related to EGFR/MAPK3/1 Signaling Pathway

Published on: May 10, 2024

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
NF-kB-dependent Signaling Pathway02:26

NF-kB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...